Company Overview
Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD). Leading its pipeline for ADHD are two drug candidates: CTx-1301 (dexmethylphenidate), which is currently progressing through Phase 3 clinical trials, and CTx-1302 (dextroamphetamine). The company is also engaged in the advancement of CTx-2103, a candidate intended for the management of anxiety disorders. Founded in 2012, Cingulate Inc. maintains its corporate headquarters in Kansas City, Kansas.
